Biotech RadarJobs updated

COMPANY

BriaCell Therapeutics

HQ: Philadelphia, PA source · briacell.com ↗ · Canada

Clinical Phase 3

Keywords: cancer oncology breast cancer cell therapy Breast Neoplasm Metastatic Breast Cancer Breast Cancer Metastatic Breast Tumor metastatic prostate cancer End Stage Cancer Cancer of Breast Cancer of the Breast Malignant Tumor of Breast Breastcancer

Location: Philadelphia, PA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$72.1MRaised (2 yrs)4Trials (company is sponsor)3NIH grants

Funding and NIH signals

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

  1. Raise Follow-on offering: $4.7M (total, as published), announced May 31, 2026. Source: SEC filing. source ↗
  2. Partnership Partnership / licensing: upfront not published; stated deal value CAD 1.18M (kept separate from upfront), announced Feb 18, 2026. Source: SEC filing. source ↗
  3. Raise Follow-on offering: $30M (total, as published), announced Jan 15, 2026. Source: SEC filing. source ↗
  4. Raise Follow-on offering: $15M (total, as published), announced Jul 16, 2025. Source: SEC filing. source ↗
  5. Raise Follow-on offering: $13.8M (total, as published), announced Apr 28, 2025. Source: SEC filing. source ↗
  6. Raise Follow-on offering: $3.05M (total, as published), announced Feb 5, 2025. Source: SEC filing. source ↗
  7. Raise Follow-on offering: $5.55M (total, as published), announced Dec 13, 2024. Source: SEC filing. source ↗
  8. Trial start Phase 1/Phase 2: A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer source ↗
  9. Trial start Phase 3: Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. source ↗
  10. Trial start Phase 1/Phase 2: Combination Study of SV-BR-1-GM With Retifanlimab source ↗
  11. Trial start Phase 1/Phase 2: SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $72.1M. Last 2 years.

Clinical trials (lead sponsor) 4

RecordTitlePhaseStatusStartPrimary completion
NCT06072612Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.Phase 3RecruitingDec 5, 20232027-12 (estimated)
NCT03328026Combination Study of SV-BR-1-GM With RetifanlimabPhase 1/Phase 2CompletedMar 16, 2018Mar 24, 2026 (actual)
NCT06471673A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast CancerPhase 1/Phase 2Unknown status (ClinicalTrials.gov)May 29, 2024Apr 30, 2025 (estimated)
NCT03066947SV-BR-1-GM in Metastatic or Locally Recurrent Breast CancerPhase 1/Phase 2CompletedMay 5, 2017Nov 22, 2018 (actual)

NIH awards 3

Annual award amounts. Total $2.5M.

Feedback